We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MANU:NYSEManchester Analysis

Data as of 2026-05-29 - not real-time

$20.87

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Manchester United’s stock is riding a strong technical backdrop – the 20‑day SMA sits above the 50‑day and 200‑day averages, RSI hovers in the upper‑mid‑range and the MACD line is bullish, with price holding above a solid support near $18 and eyeing resistance around $23. Volume is accelerating and beta is near market neutrality, yet 30‑day volatility remains elevated, signaling price swings can be pronounced. The latest earnings beat and the club’s Champions League qualification have sharpened the upside narrative, pushing analyst sentiment to a “buy” and lifting the target median toward $26.
Fundamentally, the business shows robust revenue growth and high gross margins, but profitability remains elusive with a negative profit margin and a trailing loss per share. The balance sheet is strained – debt dwarfs cash, yielding a debt‑to‑equity ratio well above 400%, and the DCF‑derived fair value near $9 is far below the current $20‑plus price, flagging the stock as overvalued. No dividend is paid, and while the brand’s global appeal offers long‑term growth potential, the valuation gap and leverage temper the outlook.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 8/10

Key Factors

  • Earnings beat and upgraded outlook
  • Bullish technical indicators (SMA crossover, MACD, RSI)
  • Increasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • High leverage and debt‑to‑equity ratio
  • Current price well above DCF fair value
  • Sustained brand strength and Champions League participation

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Persistent valuation disconnect
  • Negative profitability and limited cash flow generation
  • Absence of dividend and elevated financial risk

Key Metrics & Analysis

Financial Health

Revenue Growth18.00%
Profit Margin-2.65%
P/E Ratio141.4
ROE-9.62%
ROA0.02%
Debt/Equity421.36
P/B Ratio14.2
Op. Cash Flow$114.9M
Free Cash Flow$-10319500
Industry P/E17.1

Technical Analysis

TrendBullish
RSI59.6
Support$18.08
Resistance$22.94
MA 20$19.52
MA 50$18.15
MA 200$16.94
MACDBullish
VolumeIncreasing
Fear & Greed Index93.98

Valuation

Fair Value$8.87
Target Price$25.99
Upside/Downside24.54%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.96
Volatility59.93%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.